	Des Atouts		Date
Acadia Pharmaceuticals	USD 1.56B	233.42M	2025-12
Alnylam Pharmaceuticals	USD 4.97B	114.67M	2025-12
Amgen	USD 90.59B	445M	2025-12
BioCryst Pharmaceuticals	USD 446.42M	10.76M	2025-09
Biogen	USD 29.44B	232M	2025-12
BioMarin Pharmaceutical	USD 7.59B	20.85M	2025-12
Cytokinetics	USD 1.42B	12.02M	2025-12
Daiichi Sankyo	JPY 3.82T	252.52B	2025-12
Enanta Pharmaceuticals	USD 329.5M	48.77M	2025-12
Esperion Therapeutics	USD 364.02M	16.93M	2025-09
Gilead Sciences	USD 59.02B	490M	2025-12
Incyte	USD 6.96B	627.62M	2025-12
Ionis Pharmaceuticals	USD 3.52B	490.91M	2025-12
Ironwood Pharmaceuticals	USD 396.06M	53.12M	2025-09
Karyopharm Therapeutics	USD 96.23M	8.65M	2025-09
Novartis	USD 107.29B	2.89B	2025-09
Pfizer	USD 208.73B	2.64B	2025-09
PTC Therapeutics	USD 2.9B	255.07M	2025-12
Puma Biotechnology	USD 202.86M	7.95M	2025-09
Roche Holding	CHF 100.7B	5.94B	2025-12
Sangamo BioSciences	USD 97.56M	11.39M	2025-06
Sarepta Therapeutics	USD 3.35B	143.73M	2025-12
TG Therapeutics	USD 1.06B	38.23M	2025-12
Ultragenyx Pharmaceutical	USD 1.53B	341.56M	2025-12
Vertex Pharmaceuticals	USD 25.64B	780.7M	2025-12
Xencor	USD 875.5M	6.68M	2025-12

PTC Therapeutics Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.